Supplementary modeling results

Analysis of the drop in dopamine release, as produced in models based on the desensitization versus activation of !7 NNRs
We simulated the responses of two versions of the model to the same stimulation pattern: the partial !7 agonist TC-7020 and nicotine were systemically applied with a 30-s interval (upward arrows in Fig. S2 E) . Note that the dopamine response of the model depended on two balances: that between receptor activation and desensitization, and that between excitation and inhibition of the dopamine neuron.
As explained in the main text, the desensitization model represented the case where the !7 agonist desensitized NNRs located on the dopamine neuron itself or excitatory terminals afferent to it, with little or no influence from GABA neurons (see Fig. 2A ).
In the activation model !7 agonists reduced dopamine release by activating NNRs located on glutamatergic afferents to GABAergic interneurons in the VTA (Fig. 3A) . Figure S2 shows the time-course of the key model variables. Most importantly, both the desensitization model (left) and the activation model (right) generated the observed drop in dopamine release after TC-7020 administration, followed by a brisk rise after nicotine injection (Fig. S2 A) . A distinctive feature, however, was that the activity of the GABA neurons slightly increased after TC-7020 injection in the activation model (red curve in right panel of Fig. S2 B) , whereas it fell concomitantly with the drop in activity of the dopamine neurons in the desensitization model (panel B left). Indeed, in the desensitization model, with 80% of both !7s and !4#2s located on the dopamine neuron (or its afferents), the response of the GABA neuron was a scaled-down version of the dopamine neuron's response, and the GABA neuron decreased its spike rate after TC-7020 injection because of desensitization of the residual 20% of !7s that were located on its glutamatergic afferents. (Note that the baseline levels of activity of the dopamine and GABA neurons in Fig. S2 B are irrelevant for the present study. They can easily be reversed by introducing an additional free parameter, which we avoided for the sake of clarity.)
It is further clear from the fractions of open channels in panels Fig. S2 C that, in both models, the TC-7020 response was exclusively mediated by the !7 NNRs
(desensitization vs activation), whereas the nicotine response was dominated by activation (and subsequent desensitization) of the !4#2$ channels.
For desensitization of the !7 NNRs to cause a noticeable drop in dopamine release, however, a background receptor activation by acetylcholine was needed ( Fig.   S2 C, left) . In contrast, no cholinergic tone was needed to disclose the dopamine drop in the activation model (Fig. S2 C, right) . Finally, the two models used different peak concentrations and time-courses for the applied TC-7020. The reason for using different peak concentrations is that these two models operate in different domains of the dose-response curve (see Fig. 5 ). In the activation model, the sustained presence of TC-7020 at a low concentration was needed to keep the NNRs activated, without desensitizing them all, during the whole interval of reduced dopamine release. In the desensitization model, in contrast, most of the NNRs completely desensitized and the drop in dopamine release would persist even after complete wash-out of the compound, owing to the slowness of resensitization as compared to activation. We used a faster pharmaco-kinetics for TC-7020 in the desensitization model to illustrate this latter phenomenon (compare Fig. S2 E, left vs right). The responses to slower (faster) kinetics are shown as gray traces. Note also that the reponse latencies (6-7 s in the experiments) were not modeled explicitly, but assumed to be generated by the systemic blood circulation, and by buffering in the pulmonary capillary bed (1).
Comparative model analysis
The effect of cholinergic tone The critical effect of the level of the cholinergic tone is illustrated in greater detail in Figure S3 . Clearly, a cholinergic tone was essential to the desensitization model ( Fig.   S3 A), but unnecessary, or even detrimental, in the activation model (Fig. S3 B) .
In the desensitization model (Fig. S3 A) , a weak or absent tone would reverse the observed effect of TC-7020 into an enhanced dopamine efflux (blue curve around 40 s), because of the default activation of !7 NNRs by partial agonists. In the presence of a higher cholinergic tone, however, TC-7020 did not only contribute less to receptor activation (because of saturation, and competition with acetylcholine), but it caused an even greater loss of acetylcholine-evoked current by desensitizing the
receptor. Stated otherwise, when TC-7020 desensitizes half of the !7 NNRs, it not only reduces its own effect by 50%, but also makes 50% of the receptors unavailable for the background physiological action of acetylcholine, and the latter effect is greater in absolute value the higher the tone. Much of this desensitization effect will go unnoticed in the absence of a cholinergic tone, whence our need of a higher tone in the desensitization model.
The activation model (Fig. S3 B) , in contrast, showed an opposite dependency on cholinergic tone: a high tone would unmask desensitization of the !7 NNRs on the GABA neurons' afferents (red trace in inset to Fig S3 B) . The resulting drop in activity of the GABA neurons disinhibited the dopamine neurons, so that, after a transient drop, dopamine efflux rose above baseline.
In the following analysis, we focus on the TC-7020 response and disregard the nicotine response, which was generated by identical mechanisms (activation of !4"2 NNRs) in both models alike.
The effect of agonist concentration
Because the drop in dopamine release was generated in the activation model by a window NNR current (in the GABA neuron's afferents), lower TC-7020 doses were needed (peak concentrations from 0.8 to 15 nM; Fig. S4 A, right) than in the desensitization model (from 4 to 37 nM in the left panel of Fig. S4 A) . In both models, dopamine efflux dropped faster at higher doses of TC-7020, a consequence of accelerated desensitization and activation, reflecting the nonlinearity of reaction kinetics (see also the current traces in Fig. S1 ). The depth of the drop was also dosedependent, but was bounded in the desensitization model, where a substantial tonic !4"2* component contributed to baseline dopamine release. The activation model, in contrast, was not able to maintain the drop in dopamine release at high doses of TC-7020 ( Fig. S4 A, right, black curve) because the !7 NNRs on the afferents to the GABA neurons started to desensitize after a few seconds, disinhibiting the dopamine neurons.
The effect of agonist efficacy
A distinguishing feature between the models is that in the desensitization model a full !7 agonist evoked a transient peak before the dopamine efflux dropped ( Fig. S4 B,
. In contrast, a full agonist caused dopamine concentration only to drop faster and deeper in the activation model without evoking an intial peak ( Fig. S4 B, right). In constructing these curves, we assumed that all agonists desensitized the !7
NNR to the same degree, irrespective of their efficacy (2) (3) (4) . This assumption can be made, since !7 ligands show a poor correlation between activation and residual inhibition or desensitization (M. Bencherif, unpublished data). We also simulated efficacies higher than those reported for currents recorded in vitro (> 100%), because the presence of a receptor reserve may enhance the physiological efficacy in vivo (5).
NNRs of the !7 type in particular have been suggested to prolong responses by buffering spilled-over acetylcholine (6, 7) .
The effect of co-administration of PNU-120596
PNU-120596 is a type-2 positive allosteric modulator of !7 NNRs, releasing the receptors from desensitization (8) . 
The effect of allosteric agonists
Some recently studied allosteric modulators such as 4BP-TSQ, or its (+) enantiomer GAT107, have intrinsic (allosteric) agonist activity (9, 10) . Simulating these compounds made the strongest model predictions, as they amplified the drop in (w y =0), provided the receptor has two non-cooperating binding sites (n x =n y =2). As before, parameters were set to the values given in Table 1 , except for the new free parameter w xy , which expressed the efficacy of channel opening (or desensitization)
by co-agonist receptor binding.
We calculated the !7 current to trains of 5-s puffs of acetylcholine, in the presence of varying concentrations of an !7 compound ( Figure S5 ). We first examined this co-agonist mechanism for a competitive antagonist (Fig. S5 A) , using as ligand TC-7020 but with zero efficacy and without allowing either acetylcholine or TC-7020 to desensitize the receptor. As in Smulders et al. (14) , continuous application of a low dose of antagonist potentiated the responses to puffs of 1 µM acetylcholine. With w xy = 0.3 at the activation gate, the response increased by 37%
(upper panel in Fig. S5 A) . As in Smulders et al., however, potentiation failed when higher doses of acetylcholine were used (lower panel).
We next tried to replicate, using TC-7020 at its 30% efficacy, the observations which Prickaerts et al. (11) made with the partial agonist EVP-6124 (a sequence of potentiation of the puff response, suppression by desensitization, and opening of the channel by the agonist itself). EVP-6124, however, has a very high EC 50 /DC 50 ratio, and in order to obtain desensitization in the absence of overt activation, the EC 50 for TC-7020 had to be increased from 30 to 300 nM. Even so, a cross-term weight of w xy = 20 at the activation gate gave less than 9% potentiation. If, in contrast, puffed acetylcholine was allowed to desensitize the receptor (DC 50 = 1.3 µM) in this in vitro condition (absence of cholinesterase), potentiation was readily obtained (Fig. S5 B) . It sufficed to set the cross-term weight w xy to zero at the desensitization gate (and at the activation gate as well) to obtain a potentiation of 55% (upper panel in Fig. S5 B) .
Note that this zero cross-term implied that the co-agonist pair did not desensitize the receptor, whereas each ligand in itself did. Hence, the underlying mechanism is competitive inhibition of the co-agonist pair with pairs of identical ligands, protecting the receptor from desensitization. Note also that the further increase in amplitude after a 60-s interval at 480 s is due to a partial recovery from desensitization. When the partial agonist was applied at higher concentrations (lower panel in Fig. S5 B) , desensitization overruled co-agonist potentiation and the response dropped during agonist infusion. At still higher concentrations, the partial agonist caused channel opening on its own and the baseline between puffs rose (not shown).
Although a full study of this mechanism is beyond the scope of the present manuscript, the present results show that there may be a narrow range of concentrations of both acetylcholine and partial agonist at which these ligands would cooperate, as in Fig. S5 A. As for the in vitro experiment, our results suggest that the
potentiation effect is a consequence of reduced desensitization rather than enhanced activation.
Supplementary discussion
Mesocortical versus mesolimbic dopamine release
Can the present desensitization model for the accumbal action of !7 partial agonists be extrapolated to other systems such as prefrontal cortex, where NNRs are also abundantly expressed (15)? This is an important question because !7 ligands such as AZD0328 (16) (17) (18) , EVP-6124 (11), RG3487 (19) and JN403 (20) have been reported to generate positive cognitive effects at low nanomolar or subnanomolar plasma concentrations (although for JN403 the brain concentration was reported to be higher than its EC 50 value). !7 NNR knock-out mice, in turn, show deficits in attention and memory (21) . The pro-cognitive action of !7 ligands has been ascribed to receptor activation (16, 19, 20, 22) , receptor desensitization (2, 23) , receptor antagonism (24) or to potentiation of the receptor's response to endogenous acetylcholine (10, 11) .
Moreover, !7 NNRs have been suggested to be able to exert an effect via intracellular signalling mechanisms, even when they are in a nonconducting (desensitized but strongly agonist-binding) state (25, 26) , and in the long run, compensatory mechanisms may come into play, such as up-or downregulation of receptors subtypes (27) , and changes in circuit connectivity as a consequence of synaptic plasticity.
According to the model, the acute effects will be determined by ligand-specific and circuit-specific characteristics. Ligand-specific characteristics include, apart from differences in the efficacies to activate and desensitize the receptor and in the amplitude of the window current, also cross-affinities for other receptors. The partial agonist EVP-6124, for instance, is also a functional antagonist of 5-HT 3 receptors (11), through which it may enhance the release of acetylcholine and, secondarily, dopamine (28) . Both these circuit characteristics (tone and receptor distribution) may differ between nucleus accumbens and prefrontal cortex. Whereas !7 NNRs are sparse or absent on accumbal interneurons (29, 30) , they are richly expressed on most inhibitory neurons of mouse prefrontal cortex (15) and hippocampus. In addition, whereas the cholinergic tone in nucleus accumbens is determined by intrinsic interneurons (31), prefrontal cortex receives projections from telencephalic basal nuclei, and its cholinergic tone may fluctuate significantly, from very low during slow-wave sleep to high during attention and REM sleep. As noted above and shown in Fig. 5 , a low tone will accentuate !7 activation, whereas the window for activation will be narrower and shift to lower agonist concentrations when the tone increases.
No cyclic voltammetry data are availabale for prefrontal cortex because dopamine signals may be contaminated by noradrenaline, as prefrontal cortex, unlike the basal ganglia, receives a rich innervation from locus coeruleus (32) . !7 agonists applied to prefrontal cortex through reverse dialysis, however, were found to evoke dopamine release in anaeshetized rats (33, 34) , and this release was enhanced by systemical or local application of PNU-120596 (33) . From the failure of local PNU-120596 to raise dopamine on its own in anaesthetized animals, Livingstone et al. (33, 35) concluded the endogenous cholinergic tone to be lower in prefrontal cortex than in the basal ganglia. Note that our desensitization model, which generated a drop in dopamine release in the presence of a high cholinergic tone, also generated dopamine efflux when the tone was low or absent (blue curve in Fig. 2B ). In accordance with this, only very small doses of an !7 partial agonist, systemically applied in awake cats, were able to enhance dopamine release in the prefrontal cortex (17) ; and in behaving monkeys, only low doses of iontophoretically applied agonist enhanced persistent firing in pyramidal cells (18) .
To further speculate on this, we suggest that !7 agonists act by activating NNRs when the cholinergic tone is low. For instance, memory consolidation in hippocampus is known to require a low cholinergic tone (36) and under such conditions preterminal !7 NNRs may promote synaptic plasticty (37) (38) (39) (40) . At higher cholinergic tone, such as that observed during attention, !7 agonists may act by desensitizing NNRs, and hence for instance sharpening the cholinergic transients thought to improve attential performance (6, 41) . Figure S1 
